Información:
Error:
ID
34167
Descripción
Cardiotoxicity of Adjuvant Trastuzumab; ODM derived from: https://clinicaltrials.gov/show/NCT00858039
Link
https://clinicaltrials.gov/show/NCT00858039
Palabras clave
Versiones (1)
- 14/1/19 14/1/19 -
Titular de derechos de autor
see on clinicaltrials.gov
Subido en
14 de enero de 2019
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Breast Neoplasms NCT00858039
Eligibility Breast Neoplasms NCT00858039
- StudyEvent: Eligibility
Similar models
Eligibility Breast Neoplasms NCT00858039
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
ID.1
Item
female 18 years or older
boolean
ID.2
Item
histologically confirmed, completely excised invasive breast cancer with her-2 overexpression
boolean
ID.3
Item
primary surgery less than twelve weeks prior to registration
boolean
ID.4
Item
lvef>50% as assessed by transthoracic echocardiogram or gated heart pool scan
boolean
ID.5
Item
eastern cooperative oncology group performance status 0-2
boolean
ID.6
Item
adjuvant systemic treatment plan comprises at least three cycles of anthracycline chemotherapy and 52 weeks of trastuzumab
boolean
ID.7
Item
before patient registration, informed consent must be given according to local regulations.
boolean
ID.8
Item
pregnancy
boolean
ID.9
Item
distant metastases from breast cancer
boolean
ID.10
Item
any systemic chemotherapy prior to study entry
boolean